Amprius Technologies 2025 Q2 Earnings Narrowed Losses Amid Record Revenue

Generated by AI AgentAinvest Earnings Report Digest
Friday, Aug 8, 2025 5:10 pm ET2min read
Aime RobotAime Summary

- Amprius (AMPX) reported $15.1M Q2 revenue (350% YoY), driven by 96% battery product sales and SiCore platform scaling.

- Net losses narrowed to $6.37M (-$0.05/share) vs. $12.52M (-$0.13/share) in 2024, with first-ever positive gross margins.

- CEO highlighted growth in drones/e-mobility markets and partnerships with Amazon/AALTO, projecting $26.4M H1 2025 revenue.

- Despite 39.6% MTD stock gains, 30-day post-earnings strategies showed -50.18% excess returns over three years.

Amprius Technologies (AMPX) delivered a marked improvement in its financial performance in Q2 2025, with a 61.5% reduction in per-share losses and a 49.1% drop in net losses, though it continues to report losses for the fourth consecutive year. The results came in line with the company’s strategic focus on scaling its SiCore platform and expanding into key markets. did not provide specific financial guidance for the remainder of 2025.

Amprius Technologies reported total revenue of $15.07 million in Q2 2025, reflecting a significant 350.4% year-over-year increase. This growth was driven by robust demand for battery products, with sales of battery products contributing $14.54 million, or nearly 96% of total customer revenue. The company also generated $325,000 from customization design services, underscoring its expanding product offerings, and $200,000 in government grants. These figures highlight the company’s increasing commercial traction, particularly in high-demand sectors like electric mobility and drones.

Despite the record revenue, Amprius narrowed its net loss to $-6.37 million, or $0.05 per share, in Q2 2025 compared to $-12.52 million, or $0.13 per share, in the same period the previous year. This represents a significant improvement in financial efficiency, although the company remains unprofitable. The EPS result can be viewed as a modest positive given the context of ongoing losses.

The stock experienced a 3.50% drop during the latest trading day but has shown strong momentum with an 11.40% gain in the most recent trading week and a 39.60% increase month-to-date. However, a strategy of buying shares after a revenue increase quarter-over-quarter and holding for 30 days has not yielded positive returns, with a CAGR of 0.00% and an excess return of -50.18% over the past three years. The strategy showed no volatility or maximum drawdown, yet failed to generate any meaningful gains.

CEO John Mulcahy highlighted the company’s record $15.1 million in Q2 revenue and its first-ever positive gross margins, emphasizing the commercial success of the SiCore platform. With a 350% year-over-year revenue increase and 34% growth from Q1 2025, he underscored Amprius’ leadership in high-energy density silicon anode batteries, driven by growing adoption in drones and partnerships with global leaders such as AALTO and . Mulcahy expressed optimism about future growth in electric mobility and sustainability-focused markets.

Amprius expects continued momentum in SiCore platform adoption and production scaling, both through internal pilot lines and contract manufacturing. The company also anticipates leveraging its inclusion in Amazon’s Climate Tech Accelerator to explore new applications in consumer electronics and mobility. For the first half of 2025, Amprius has already generated $26.4 million in revenue, surpassing its 2024 full-year total.

Additional News
Recent global news highlights include heightened geopolitical tensions, particularly in the Middle East, where rifts continue over Gaza-related plans, and the UN warns against the catastrophic humanitarian situation in the region. In the Americas, Trump has taken several economic policy actions, including ordering the U.S. Census to exclude illegal immigrants and nominating a key economic adviser to the Federal Reserve Board. In Europe, Portugal is extending national alerts due to an ongoing wildfire crisis, while EU pharmaceutical companies prepare for potential impacts from U.S. tariffs. In Asia-Pacific, India has responded to increased levies, and Cambodia and Thailand have signed a ceasefire agreement.

Comments



Add a public comment...
No comments

No comments yet